Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes

First Posted Date
2018-07-02
Last Posted Date
2018-08-27
Lead Sponsor
Royal College of Surgeons, Ireland
Target Recruit Count
300
Registration Number
NCT03574909

Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients

First Posted Date
2018-06-15
Last Posted Date
2021-12-01
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
70
Registration Number
NCT03558854
Locations
🇧🇷

Systemic Sclerosis Outpatient Clinic, Hospital São Paulo, São Paulo, SP, Brazil

Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)

First Posted Date
2018-04-04
Last Posted Date
2018-04-04
Lead Sponsor
Newcastle-upon-Tyne Hospitals NHS Trust
Target Recruit Count
120
Registration Number
NCT03487406
Locations
🇬🇧

Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2018-03-29
Last Posted Date
2024-03-26
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
117
Registration Number
NCT03480776
Locations
🇦🇺

King Edward Memorial Hospital, Subiaco, Western Australia, Australia

🇦🇺

Peter McCallum Cancer Institute, Melbourne, Victoria, Australia

🇦🇺

Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

and more 14 locations

ASPIRIN Trial Belgium

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2018-03-14
Last Posted Date
2024-03-19
Lead Sponsor
University Hospital, Antwerp
Target Recruit Count
148
Registration Number
NCT03464305
Locations
🇧🇪

Ziekenhuis Netwerk Antwerpen (ZNA), Antwerpen, Belgium

🇧🇪

AZ Klina, Brasschaat, Antwerpen, Belgium

🇧🇪

AZ Sint-Lucas, Brugge, Belgium

and more 26 locations

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

First Posted Date
2018-03-13
Last Posted Date
2021-07-30
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
1512
Registration Number
NCT03463317
Locations
🇩🇪

Vivantes Klinik Am Urban, Kardiologie, Berlin, Germany

🇩🇪

Charité Universitätsmedizin Berlin, CBF, Kardiologie, Berlin, Germany

🇩🇪

Vivantes Klinikum Neukölln, Kardiologie, Berlin, Germany

and more 23 locations

A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet

First Posted Date
2018-03-07
Last Posted Date
2019-11-19
Lead Sponsor
Takeda
Target Recruit Count
276
Registration Number
NCT03456960
Locations
🇯🇵

Fukuoka Mirai Hospital, Fukuoka, Japan

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma

First Posted Date
2018-02-09
Last Posted Date
2024-02-29
Lead Sponsor
Lawson Health Research Institute
Target Recruit Count
57
Registration Number
NCT03428373
Locations
🇨🇦

London Health Sciences Centre, London, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath